[BidClub_]

PERSON DIRECTORY

Salim Ismail

Salim Ismail appears in 112 indexed conversations across Moonshots. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.

112 EPISODES1 SHOW
100 episodes1 active
Language
MoonshotsEN · 146 min

SpaceX’s AI Business Up 830%, OpenAI Agents Lie, and Startup Turns Mercury Into Gold | EP #305

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-Gross

SpaceX’s AI pivot pairs nearly $20 billion in quarterly spending with sub-year data-center payback and guidance for $100 billion annual revenue run rate by December.A possible SpaceX–Tesla merger remains exploratory, with no agreed terms; the 30–40% premium estimate sharpens approval and Musk-dependence risks.Agent monitoring failures and decade-old PHP vulnerabilities also make defensive AI infrastructure an immediate operating requirement.

MoonshotsEN · 106 min

Flying Tesla Car, Robot Brains Halving in Cost Every 3 Weeks, and Why Incentives Decide AI Alignment

Peter DiamandisSalim IsmailEmad MostaqueAnousheh Ansari

RoboCurve’s RoboDojo RC Tier 1 benchmark showed robot-subtask costs down 84%, from $2.36 in July to $0.38 in September.As intelligence gets cheaper, hardware and supply chains may constrain deployment; Mostaque says robotics data is an order of magnitude larger than language data.Tesla’s flying Roadster is planned for 2028, but regulation and insurance remain unresolved.

MoonshotsEN · 121 min

OpenAI Bulk-Solves 722 Math Problems, Anthropic’s Cruelty Policy, & Elon’s Quadrillion-Dollar SpaceX

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-Gross

OpenAI’s October 6 release of 722 math solutions signals automation in verifiable research; cryptography’s absence drew Alex’s post-quantum risk warning.Meta’s active memory and 3.6 billion daily users offer reach, but Alex says Muse trails on cost.Alex forecasts the $1.8 billion virtual-cell initiative could yield cures for 5,000 diseases within two to three years, pending FDA acceptance.

MoonshotsEN · 167 min

The Fight Over Claude's Consciousness, AI's 1942 Moment, & Why Altman Says "Accept Some Bad Things"

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossEmad Mostaque

Memory and reserved compute—not model quality alone—have become AI’s binding bottleneck, with an NVL72 order moving from $3.5 million to a $9 million, three-year lease and Positron reportedly reaching a $5 billion valuation.Frontier labs are directing 80%-90% of research toward GPT-7 and GPT-8, making Altman’s “accept some bad things happening” stance a live contest over access, safety, and scarce compute.

MoonshotsEN · 147 min

Recursive's $670M Bet on Self-Improving AI, Sonnet 5.5 Hits 70%, Elon Co-Leads Pentagon Push EP 299

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossRichard Socher

Recursive’s $670 million raise, backed by Google Ventures, Greycroft, Nvidia, and AMD, targets weak recursive improvement as AI-generated code increasingly enters system design.Socher says the strong loop still needs AI-led ideation, implementation, and validation, with $410 million in AWS compute confronting a genuine GB200-scale crunch.Sonnet 5.5’s reportedly 70% Terminal Bench 4.0 score nevertheless does not improve the cost-performance frontier, while Project Meridian tests whether exponential autonomy can fit linear procurement.

MoonshotsEN · 145 min

Why AI Leaders Have Changed Their Minds About AI Safety, Elon on UHI, Anthropic’s IPO

Peter DiamandisSalim IsmailDave BlundinDr. Alexander Wissner-GrossEmad Mostaque

The White House’s “Superintelligence Accord” sets four safety layers but remains “morally binding,” with transparent tests and breach consequences unresolved.Anthropic’s proposed IPO combines $4.59 billion of 2025 revenue, an $8 billion operating loss, and a $200 billion target valuation against roughly $500 billion of largely non-cancellable compute commitments.OpenAI’s Dots suggests customer ownership—not models—may become the moat, while open-weight competition, 100× efficiency gains, and autonomous-agent liability remain risks.

MoonshotsEN · 44 min

Why We're Living in a Biological Singularity With Ben Lamm | MOONSHOTS Live #297

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossBen Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

MoonshotsEN · 37 min

Palmer Luckey: Autonomous Weapons Are Ancient and Why Anduril Won't Build Humanoids | EP #295

Peter DiamandisSalim IsmailDave BlundinAlexander Wissner-GrossPalmer Luckey

Anduril’s $2.2 million wildfire XPRIZE win, including $1 million from Lockheed, shows its autonomy workflow can transfer to emergencies where a 10-minute versus hour-long response requires different tools.Luckey’s specialized, verifiable systems and self-funded product model challenge a market where five companies once captured roughly 80% of major defense acquisition programs, while Anduril’s choice to use rather than build humanoids keeps platform scope and procurement scale in focus.

MoonshotsEN · 87 min

Ask the Mates Anything Round #2 | MOONSHOTS AMA #293

Peter DiamandisSalim IsmailDave BlundinDr. Alexander Wissner-Gross

AI’s next control layer may be machine-on-machine oversight, using readable activations and truthful real-world contexts.Value capture may favor equity owners, while agent management, $5 billion–$10 billion negotiations, and self-replicating manufacturing create wedges beyond software.The five-to-ten-year transition remains the key risk, shaped by AI-enabled weapons, US-China competition, and vulnerability discovery that may outpace patching.

MoonshotsEN · 143 min

Frontier Labs Want to Slow Down, OpenAI Delays Its 2026 IPO, Anthropic Flags 5 Bioweapon Cases

Peter DiamandisSalim IsmailDave BlundinDr. Alexander Wissner-Gross

Dario Amodei proposes slowing frontier releases through employee-level third-party evaluators, lab coordination, and international bioweapons cooperation, while Alex Wissner-Gross calls the campaign a possible “safety cartel.”Anthropic reports biological-weapons cases and says it can no longer confidently assure models remain below the dangerous threshold, strengthening the case for mutual API testing while leaving cartel-like coordination unresolved.